Heart risk is visible earlier than the system acts on it

Three studies, one gap

Three medRxiv preprints look at heart and kidney disease from three angles, and they describe the same gap from different sides. One builds a lifetime cardiovascular risk model and finds younger patients that 10-year scores miss. One studies prescribing after heart failure hospitalization and finds that whether a patient gets guideline treatment depends heavily on which provider they see. And one tracks chronic kidney disease patients and finds a small but important group whose heart and kidneys fail together within a year. All three are preprints, so none of this is peer-reviewed yet. Read together, they say the risk is visible earlier than the system acts on it. m:…0950 m:…5281 m:…0914

A lifetime lens finds younger patients

The risk model is QRISK4-Lifetime, which extends cardiovascular risk prediction to age 95. Validated across 13 million adults, it achieved C-indices of 0.860 in women and 0.845 in men, matching the performance of the established QRISK4 model at the 10-year horizon. The point of the lifetime lens is who it catches: the model identified a group making up 8.1% of the total with high lifetime risk who fell below the 10% 10-year risk threshold, and 72.8% of that group were under 40 years old. These are people a 10-year score would call low risk, in a decade of life when prevention has the longest runway. The preprint presents lifetime risk assessment as a complement to 10-year risk assessment in clinical prevention discussions, not a replacement: the two horizons answer different questions, and the lifetime view is the one that speaks to younger adults. m:…0950

Treatment depends on who you see

The prescribing preprint shows what happens after the risk becomes an event. Studying heart failure patients in the Veterans Affairs system, it found provider-level variation in ARNI and SGLT2i use after heart failure hospitalization that was substantial and independent of site-level clustering: the variation lives with individual providers, not just with hospitals. A large proportion of patients remained untreated after hospitalization despite established guidelines. Cardiology visits were associated with the highest adjusted odds of ARNI use, at an odds ratio of 2.30, and SGLT2i use, at 1.99, compared with other specialties. Pharmacist visits were independently associated with increased use of both drugs, at odds ratios of 1.14 for ARNI and 1.15 for SGLT2i. The implication drawn in the preprint is that interventions should focus on individual provider behaviour, since that is where the variation sits. m:…5281

When heart and kidney fail together

The third preprint, from the Chronic Renal Insufficiency Cohort study of 3,557 patients, looks at the patients for whom the gap closes fastest. It found that 4.5% of chronic kidney disease patients without baseline heart failure developed progressive cardiorenal syndrome, defined as heart failure and end-stage kidney disease within 12 months. Higher albumin to creatinine ratio was a strong predictor, with a hazard ratio of 2.44, and novel biomarkers including TNF-alpha and GDF-15 were associated with progressive cardiorenal syndrome. Risk factors varied by the sequence of events, with heart failure before end-stage kidney disease looking different from end-stage kidney disease before heart failure, suggesting distinct pathways rather than one shared decline. For clinicians, the value is stratification: a small group can be identified early, and the markers that identify them include both routine measures and newer biomarkers. m:…0914

What to watch

The three preprints point at decisions that are already available to health systems, even before peer review settles the details. A lifetime risk view changes who gets a prevention conversation, and the QRISK4-Lifetime numbers say the newly visible group is mostly under 40. A prescribing gap that sits with individual providers rather than sites points at provider-level interventions, and the data say cardiology involvement and pharmacist visits are the levers that already correlate with treatment. A cardiorenal syndrome that arrives within 12 months for about one in twenty patients without baseline heart failure points at earlier monitoring for the highest-risk kidney patients. What remains unknown is whether acting on these signals changes outcomes: whether lifetime risk discussions lead to earlier treatment, whether provider-level interventions close the prescribing gap, and whether the cardiorenal biomarkers hold up outside the CRIC cohort. All three preprints need that follow-up before they become practice. m:…0950 m:…5281 m:…0914